Sign In
Buy NDAQ
$81.61
-0.88 (-1.07%)
At Close: Jun 24, 2026
Primis Financial Corp. Announces Reauthorization of Stock Repurchase Program and Compliance with Nasdaq Listing Rules
05:25pm, Thursday, 19'th Dec 2024
MCLEAN, Va. , Dec. 19, 2024 /PRNewswire/ -- Primis Financial Corp. (NASDAQ: FRST) ("Primis" or the "Company"), today announced that the board of directors of the Company (the "Board") approved a stock
Prestige Wealth Inc. regains compliance with Nasdaq minimum bid price requirement
04:30pm, Thursday, 19'th Dec 2024
HONG KONG, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prestige Wealth Inc. (NASDAQ: PWM) (“PWM”, or the “Company”), a wealth management and asset management services provider based in Hong Kong, today
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
04:10pm, Thursday, 19'th Dec 2024
AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company fo
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 19'th Dec 2024
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
Aptose Announces Positive Decision by Nasdaq Hearings Panel
04:05pm, Thursday, 19'th Dec 2024
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
02:28pm, Thursday, 19'th Dec 2024
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRN
ETF of the Week: iShares Nasdaq Top 30 Stocks ETF (QTOP)
12:38pm, Thursday, 19'th Dec 2024
VettaFi's Head of Research Todd Rosenbluth discussed the iShares Nasdaq Top 30 Stocks ETF (QTOP) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, info
Berkshire Hathaway Chairman Warren Buffett is a value investor at his core. Value investing involves finding stocks trading below their intrinsic value and buying them at a discount.
New Era Helium to Ring Nasdaq Opening Bell, Kicking Off 2025 Trading on January 2, 2025
07:30am, Thursday, 19'th Dec 2024
MIDLAND, Texas--(BUSINESS WIRE)--New Era Helium, Inc. (NASDAQ:NEHC) (“NEH,” “New Era Helium,” or the “Company”), an exploration and production (E&P) company sourcing helium produced in ass
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 19'th Dec 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employee
MindMed to Be Added to the Nasdaq Biotechnology Index
07:00am, Thursday, 19'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain heal
Climb Bio to be Added to the Nasdaq Biotechnology Index
07:00am, Thursday, 19'th Dec 2024
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)
History Says the Nasdaq Will Surge in 2025. 1 Stock-Split Stock to Buy Before It Does.
06:00am, Thursday, 19'th Dec 2024
The U.S. stock market has been on a winning streak in 2024, with the technology-heavy Nasdaq Composite index topping the 20,000 mark. A major part of this rally can be attributed to the rapid adoption
Why Nasdaq-100 Leveraged ETF TQQQ Is Falling
06:50pm, Wednesday, 18'th Dec 2024
The ProShares UltraPro QQQ TQQQ, which provides triple-leveraged exposure to the Nasdaq-100 Index, fell some 10.81% to $82.09 Wednesday after the Federal Reserve's December meeting.
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
08:00am, Wednesday, 18'th Dec 2024
WALTHAM, Mass. , Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combi
